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Abstract
Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II
JAKARTA2 study assessed fedratinib in patients with intermediate- or high-risk
myelofibrosis (MF) who were resistant or intolerant to prior ruxolitinib per investi-
gator assessment. Patients received fedratinib 400 mg/day in 28-day cycles. The
JAKARTA2 outcomes were initially reported using a last-observation-carried for-
ward (LOCF) analysis in a “Per Protocol” population. This updated analysis of
JAKARTA2 employs intention-to-treat analysis principles without LOCF for all
treated patients (ITT Population; N = 97), and for a patient subgroup who met more
stringent definitions of prior ruxolitinib failure (Stringent Criteria Cohort; n = 79).
Median duration of prior ruxolitinib exposure was 10.7 months. The primary end-
point was spleen volume response rate (SVRR; ≥35% spleen volume decrease from
baseline to end of cycle 6 [EOC6]). The SVRR was 31% in the ITT Population and
30% in the Stringent Criteria Cohort. Median duration of spleen volume response
was not reached. Symptom response rate (≥50% reduction from baseline to EOC6
in total symptom score [TSS] on the modified Myelofibrosis Symptom Assessment
Form [MFSAF]) was 27%. Grade 3-4 anemia and thrombocytopenia rates were 38%
and 22%, respectively. Patients with advanced MF substantially pretreated with
ruxolitinib attained robust spleen responses and reduced symptom burden with
fedratinib.
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1 | INTRODUCTION
Myelofibrosis (MF) is life-threatening BCR-ABL1-negative myeloprolif-
erative neoplasm (MPN) characterized by stem cell-derived clonal
myeloproliferation, abnormal cytokine expression, bone marrow fibro-
sis, splenomegaly, constitutional symptoms, leukemic progression, and
poor survival.1,2 MF can present de novo (primary MF), or develop
secondary to antecedent polycythemia vera (PV) or essential
thrombocythemia (ET). MF symptoms, including fatigue, night sweats,
pruritus, and splenomegaly-related symptoms (eg, early satiety and
abdominal discomfort or pain) markedly impair quality of life.3 For
patients with intermediate-2 or high risk MF per the Dynamic Interna-
tional Prognostic Scoring System Plus (DIPSS-Plus), estimated median
overall survival (OS) is only 2.9 years and 1.3 years, respectively.4 Cur-
rently, allogeneic stem cell transplantation is the only potentially cura-
tive option for MF, but most patients are not eligible for transplant
due to comorbidities and general health status.5-7
In MF, aberrant constitutive activation of the JAK-signal trans-
ducer and activator of transcription (STAT) pathway results in clonal
expansion of malignant myeloproliferative cells.8 A majority of
patients with MF harbor a JAK2 V617F mutation. Mutations in JAK2
and in the MPN driver genes, myeloproliferative leukemia virus (MPL)
and calreticulin (CALR), upregulate JAK-STAT signaling with increased
downstream transcription and gene expression. Approximately 10%
of patients with MF do not have a JAK2, MPL, or CALR mutation; this
is referred to as “triple-negative” disease.2
Until recently, ruxolitinib, a dual JAK1/JAK2 inhibitor, was the
only therapy approved for treatment of intermediate- and high-risk
MF. Ruxolitinib can improve splenomegaly and symptom scores in
patients with primary, post-PV, or post-ET MF.9-11 Many patients
treated with ruxolitinib lose response over time, achieve only a sub-
optimal response, or develop cytopenias during treatment, resulting in
therapy discontinuation.12 The combined ruxolitinib discontinuation
rate in the phase III COMFORT-I and COMFORT-II trials was ~50% at
3 years and ~72% at 5 years.13,14-16 A retrospective review of data
from two large United States (US) claims databases suggests
ruxolitinib discontinuation rates in clinical practice during early treat-
ment are at least as high as rates in clinical trials.17 The prognosis for
these patients is generally poor, with median survival ranging from
6 to 28 months, depending on whether a patient is in the chronic
phase of MF or has transitioned into the blast phase when ruxolitinib
was discontinued.12,18-20 There is no approved standard of care for
patients with MF previously treated with ruxolitinib; thus, there is an
important medical need for an effective therapy in this setting.
Fedratinib is an oral kinase inhibitor with activity against wild-
type and mutationally activated JAK2 and FMS-like tyrosine kinase
3 (FLT3). It was approved by the US Food & Drug Administration
(FDA) in August 2019 for treatment of adult patients with
intermediate-2 or high-risk primary or secondary (post-PV or post-ET)
MF.21 Fedratinib was recently added to the National Comprehensive
Care Network guidelines for treatment of MPNs, as an initial treat-
ment option for patients with intermedicate-2 or high-risk MF or as
second-line therapy for those who do not respond or lose response to
ruxolitinib.1 Fedratinib has higher inhibitory activity for JAK2 over
family members JAK1, JAK3 and TYK2, and is a more selective inhibi-
tor of JAK2 than ruxolitinib.22 Additionally, an in vitro drug screen
identified 211 mutations resistant against ruxolitinib that were fully
sensitive to fedratinib,23 perhaps by a novel mechanism of JAK2
kinase inhibition by fedratinib that prevents emergence of genetic
resistance, making it a therapeutic option for patients who are resis-
tant to ruxolitinib therapy. Fedratinib also has a longer effective half-
life than ruxolitinib (~41 hours vs 3 hours, respectively), which allows
more persistent JAK2 inhibition and makes it suitable for once-daily
dosing.24,25
The international, single-arm phase II JAKARTA2 trial evaluated
the efficacy and safety of fedratinib in patients with intermediate- or
high-risk primary MF, post-PV MF, or post-ET MF, who were previ-
ously treated with ruxolitinib. The fedratinib clinical development pro-
gram was placed on clinical hold in November 2013 by the US FDA
following reports of suspected Wernickeʼs encephalopathy (WE), a
rare but serious neurological condition. As a result, the JAKARTA2
trial was terminated; all patients were required to discontinue
fedratinib treatment and the study was substantially truncated.
Note, JAKARTA2 enrolled patients who were resistant or intoler-
ant to prior ruxolitinib therapy based on investigator assessment. The
primary endpoint was the spleen volume response rate (SVRR); that is,
the proportion of patients who achieved a ≥35% reduction from base-
line spleen volume at the end of cycle 6 (EOC6). Based on the pro-
spective Statistical Analysis Plan, the primary efficacy analysis of
JAKARTA2 was performed in the Per Protocol population, which com-
prised patients with spleen volume assessments at baseline and at
least one post-baseline time point. The original analysis utilized a last-
observation-carried-forward (LOCF) analysis method, which allowed
for the last spleen volume assessment to be “carried forward” for
patients missing EOC6 assessments.26 At EOC6, the SVRR (using
LOCF method) in the Per Protocol population was 55% (95% confi-
dence interval [CI] 44, 66).26
The objectives of this updated analysis are to confirm the efficacy
of fedratinib in the JAKARTA2 study by employing intention-to-treat
(ITT) analysis principles for all treated patients. There is no imputation
made for missing data, and to demonstrate efficacy outcomes in a
subgroup of JAKARTA2 patients who met new, more stringent criteria
for relapsed, refractory, or intolerant to ruxolitinib than were used in
the original analysis. Additionally, a sensitivity analysis assessed
fedratinib efficacy in patients who met the more stringent criteria for
ruxolitinib failure, and for whom the primary endpoint would have
been least affected by early termination of the study.
2 | METHODS
The phase II, international, multicenter, open-label, single-arm
JAKARTA2 study (ClinicalTrials.gov NCT01523171) was conducted at
40 sites in 10 countries. The study protocol was approved by relevant
independent ethics committees or institutional review boards at each
site. All patients provided written, informed consent before study
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participation. Detailed study design and inclusion/exclusion criteria
have been described.26 Briefly, eligible patients were aged ≥18 years,
with primary, post-PV, or post-ET MF; intermediate-1 (with symptoms),
intermediate-2, or high risk disease; palpable splenomegaly (≥5 cm
below the left costal margin); Eastern Cooperative Oncology Group
(ECOG) performance status scores ≤2; platelet counts ≥50 × 109/L,
and were considered by their treating investigator to be resistant or
intolerant to ruxolitinib (Table S1).
Patients received oral fedratinib 400 mg once-daily in repeated
28-day treatment cycles. Dose escalation was permitted up to
600 mg/day if there was <50% reduction in spleen size by palpation
at the end of cycles 2 and 4, and the fedratinib dose could be reduced,
interrupted, or discontinued in cases of toxicity.
This updated analysis assesses three patient populations
(Table S1): the ITT Population includes all patients who enrolled in
JAKARTA2; the Stringent Criteria Cohort comprises a subset of
patients who met the new, more stringent criteria for relapsed or
refractory to ruxolitinib (based on spleen volume or size assessments),
or intolerant to ruxolitinib, than used in the original analysis.26 The
Sensitivity Analysis Cohort includes the subgroup of patients within the
Stringent Criteria Cohort who were least affected by early study ter-
mination, that is, those who reached fedratinib treatment cycle six, or
discontinued fedratinib before cycle six for reasons other than “study
terminated by the sponsor”. These criteria were presented to and
accepted by MF experts from the United States and European Union
at an advisory board meeting with the study sponsor. The sponsors
also reviewed the proposed criteria with relevant health authorities.
2.1 | Efficacy endpoints
The primary endpoint was SVRR, defined as the proportion of patients
who achieved a ≥ 35% reduction in spleen volume from baseline to
EOC6. Spleen volume assessments were to be performed at baseline, at
the end of cycles three and six, and every six cycles thereafter. Blinded
review of MRI/CT scans was performed by an independent central
imaging laboratory. This updated analysis employed ITT analysis princi-
ples; thus, missing spleen volume data were not imputed (no LOCF) for
the primary endpoint, and patients missing assessments at EOC6 were
considered nonresponders. No formal statistical adjustments were made
for possible covariate effects or for multiple comparisons.
SVRR at EOC6 was also evaluated in patient subgroups defined
by baseline platelet count (50 to <100 × 109/L or ≥100 × 109/L),
baseline hemoglobin level (<10 or ≥10 g/dL), number of prior thera-
pies (≤2 or >2), age (≤65 or >65 years), JAK2 mutation status (mutant
or wild-type), and outcome of prior ruxolitinib treatment per new
stringent criteria (relapsed, refractory, or intolerant).
A key secondary endpoint was symptom response rate, defined
as the proportion of patients with a ≥50% decrease in total symptom
score (TSS) from baseline to EOC6. Symptom scores were subjectively
evaluated using the modified Myelofibrosis Symptom Assessment
Form (MFSAF27) e-diary, which assesses the severity of six key MF-
associated symptoms (night sweats, pruritis, abdominal discomfort,
early satiety, pain under ribs on left side, and bone or muscle pain),
each assigned a score from 0 (absent) to 10 (worst imaginable). TSS is
the sum of individual symptom scores. The MFSAF was to be com-
pleted beginning 7 days before cycle 1-day 1, and then 7 days before
day 1 of each subsequent treatment cycle for six treatment cycles,
and at EOC6. The MFSAF Analysis Population included patients with
evaluable TSS data available at baseline and at least 1 post-baseline
assessment. Confidence intervals for spleen volume and symptom
response rates were calculated using the Clopper-Pearson Exact
method.
Additional secondary endpoints included the duration of spleen
volume response, calculated from the date of first response to the
date of disease progression (≥25% spleen volume increase from base-
line) or death, whichever came first. Duration of spleen response was
estimated by Kaplan-Meier (KM) analysis among patients who
responded at any time on-study. In the absence of disease progres-
sion or death before the analysis cut-off date (May 7, 2014), duration
of response was censored at the date of the last valid assessment
before data cutoff. Also assessed were median percent change in
spleen volume from baseline to EOC6, proportion of patients with
≥50% reductions in spleen size by palpation at EOC6, and proportion
of patients with ≥35% reduction from baseline in spleen volume
at EOC3.
2.2 | Safety
The safety and tolerability of fedratinib were evaluated based on the
incidence of treatment-emergent adverse events (TEAEs), classified
according to the Medical Dictionary for Regulatory Activities
(MedDRA) version 20.1, and hematologic and biochemical laboratory
values. The TEAEs (preferred terms unless otherwise noted) were
graded according to National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI-CTCAE) version 4.03. A TEAE was
defined as any AE that developed, worsened, or became serious
between first dose of fedratinib to 30 days after the last dose.
Although transfusions were allowed, concomitant use of anti-anemic




In all, 97 patients were enrolled and treated in JAKARTA2 between
30 April 2012, and 7 May 2014, and comprise the ITT Population
(Figure S1). The majority of patients (n = 63; 65%) discontinued treat-
ment due to study termination following the fedratinib clinical hold.
Other common reasons for treatment discontinuation were adverse
events (19%) and disease progression (6%).
Based on new, more stringent criteria for ruxolitinib failure,
79/97 patients (81%) were refractory (n = 47; 48%), relapsed (n = 18;
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19%), or intolerant (n = 14; 14%) to prior ruxolitinib therapy and com-
prised the Stringent Criteria Cohort. The remaining 18 patients were
excluded from the Stringent Criteria Cohort because they had an ade-
quate response to ruxolitinib (n = 3), were missing ruxolitinib response
data (n = 8), or did not receive ≥3 months of ruxolitinib treatment
(n = 7). The Sensitivity Analysis Cohort included 66 patients within
the Stringent Criteria Cohort who had the opportunity to receive six
cycles of fedratinib therapy or discontinued treatment prior to cycle
six for reasons other than study termination.
The median age of all patients was 67 years (range 38-83). At entry,
patients generally had poor prognostic disease characteristics (Table 1).
Median baseline spleen volume was 2894 mL (~14 times that reported
in the healthy population28) and 93 patients (96%) reported experienc-
ing one or more MFSAF symptom at baseline. The majority (79%) of
patients had received ≥2 prior MF-directed therapies, and 13% had
received ≥4 MF-directed therapies before study entry. One-third of all
patients had baseline platelet counts of 50 to <100 × 109/L. Over one-
half (53%) of patients had baseline hemoglobin levels <10 g/dL and
14% were RBC transfusion-dependent.29 There were no overt differ-
ences in baseline characteristics between the ITT Population and the
Stringent Criteria or Sensitivity Analysis cohorts (Table 1).
In the ITT Population, the median duration of prior ruxolitinib treat-
ment was 10.7 months (range 0.1-62.4). Most patients (71%) had
received ruxolitinib at initial daily doses of 30-40 mg, with median






cohort (n = 79)
Sensitivity analysis
cohort (n = 66)
Age, years, median (range) 67 (38-83) 66 (38-83) 66 (38-83)
Disease type, n (%)
Primary MF 53 (55) 47 (60) 38 (58)
Post-PV MF 25 (26) 18 (23) 17 (26)
Post-ET MF 19 (20) 14 (18) 11 (17)
Risk status, n (%)
Intermediate-1 with
symptoms
16 (17) 11 (14) 6 (9)
Intermediate-2 47 (49) 41 (52) 35 (53)
High 34 (35) 27 (34) 25 (38)
Years since MF diagnosis,
median (range)
4.1 (0.3-24.5) 5.4 (0.4-24.5) 5.6 (0.4–24.5)
Prior ruxolitinib exposure,
months, median (range)
10.7 (0.1–62.4) 11.5 (1.0–62.4) 11.5 (1.0–62.4)
RBC transfusion dependence,
n (%)
14 (14) 13 (17) 12 (18)
MFSAF symptoms,a n (%)
Yes 93 (96) 76 (96) 64 (97)
No 4 (4) 3 (4) 2 (3)
JAK2 mutational profile, n (%)
Mutant 61 (63) 48 (61) 41 (62)
Wild-type 29 (30) 25 (32) 20 (30)
Missing 7 (7) 6 (8) 5 (8)
Platelet count, n (%)
50 to <100 × 109/L 33 (34) 28 (35) 26 (39)
≥100 × 109/L 64 (66) 51 (65) 40 (61)
Hemoglobin level, n (%)
<10 g/dL 51 (53) 46 (58) 40 (61)
≥10 g/dL 46 (47) 33 (42) 26 (39)
Spleen volume, mL, median
(range)
2894 (737-7815) 2946 (737–7815) 2998 (784-7815)
Spleen size, cm, median
(range)
18 (5-36) 18 (5-36) 18 (5-36)
Abbreviations: ET, essential thrombocythemia; ITT, intention-to-treat; JAK2, Janus kinase 2; MF, myelofi-
brosis; PV, polycythemia vera; RBC, red blood cell.
aNight sweats, itching, abdominal discomfort, abdominal pain, early satiety, or bone pain.
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cumulative ruxolitinib exposure in the ITT Population of 9540 mg
(range 80-50 480 mg). Median duration of prior ruxolitinib exposure in
the both Stringent Criteria and Sensitivity Analysis subgroups was
11.5 months (range 1.0-62.4 months).
The median number of fedratinib cycles received in the ITT Popula-
tion at the time of the clinical hold was six (range 1-20 cycles) and median
actual fedratinib dose intensity was 2000 mg/week (1403-3884 mg).
Median number of fedratinib treatment cycles in the Stringent Criteria
and Sensitivity Analysis cohorts was seven (range 1-20 cycles).
3.2 | Efficacy
3.2.1 | Spleen response
In the ITT Population, SVRR was 31% (95%CI 22%, 41%). Response
rates in the Stringent Criteria and Sensitivity Analysis cohorts
supported the robustness of efficacy findings in the ITT Population:
SVRR was 30% (95%CI 21%, 42%) in the Stringent Criteria Cohort
and 36% (25%, 49%) in the Sensitivity Analysis Cohort (Table 2). In
subgroup analyses, SVRRs were not significantly influenced by reason
for prior ruxolitinib failure (relapsed/refractory or intolerant), number
of prior anti-cancer therapies, platelet count, hemoglobin level, patient
age, or JAK2 mutational status (Table 2). In patients with platelet
counts of 50 to <100 × 109/L at study entry, SVRRs in the ITT Popu-
lation, Stringent Criteria Cohort, and Sensitivity Analysis Cohort were
36%, 39%, and 42%, respectively; and SVRRs in patients with hemo-
globin levels <10 g/dL at baseline were 28%, 26%, and 30% (Table 2).
The duration of spleen response was subject to extensive censor-
ing due to early study termination; follow-up ranged from 0 to
13.4 months. Among patients who achieved a spleen response at any
time on-study (n = 47), the estimated median duration of response
was not reached (NR; 95%CI 7.2 months, NR) (Figure S2), and only
two responders (4%) experienced disease progression or died by the
time of study termination. Only 25% of the 47 responders in the ITT
Population had a duration of response of less than 9.4 months.
TABLE 2 Subgroup analyses: Spleen volume response rates (SVRR) at end of cycle six, overall and in subgroups defined by patient
characteristics at baseline
ITT population (N = 97) Stringent criteria cohort (n = 79) Sensitivity analysis cohort (n = 66)
SVRR at EOC6 (overall), n (%) 30 (31%) 24 (30%) 24 (36%)
[95% CI] [22, 41] [21, 42] [25, 49]
Prior ruxolitinib outcome Resistanta Intoleranta Relapsed/refractoryb Intolerantb Relapsed/refractoryb Intolerantb
n = 64 n = 32 n = 65 n = 14 n = 56 n = 10
SVRR, n (%) 21 (33%) 9 (28%) 20 (31%) 4 (29%) 20 (36%) 4 (40%)
[95% CI] [22, 46] [14, 47] [20, 43] [8, 58] [23, 50] [12, 74]
Number of prior therapies ≤2 >2 ≤2 >2 ≤2 >2
n = 67 n = 30 n = 58 n = 21 n = 49 n = 17
SVRR, n (%) 23 (34%) 7 (23%) 19 (33%) 5 (24%) 19 (39%) 5 (29%)
[95% CI] [23, 47] [10, 42] [21, 46] [8, 47] [25, 54] [10, 56]
Platelet count (109/L) 50 to <100 ≥100 50 to <100 ≥100 50 to <100 ≥100
n = 33 n = 64 n = 28 n = 51 n = 26 n = 40
SVRR, n (%) 12 (36%) 18 (28%) 11 (39%) 13 (26%) 11 (42%) 13 (33%)
[95% CI] [20, 55] [18, 41] [22, 59] [14, 40] [23, 63] [19, 49]
Hemoglobin concentration (g/dL) <10 ≥10 <10 ≥10 <10 ≥10
n = 51 n = 46 n = 46 n = 33 n = 40 n = 26
SVRR, n (%) 14 (28%) 16 (35%) 12 (26%) 12 (36%) 12 (30%) 12 (46%)
[95% CI] [16, 42] [21, 50] [14, 41] [20, 55] [17, 47] [27, 67]
Patient age ≤65 >65 ≤65 >65 ≤65 >65
n = 41 n = 56 n = 36 n = 43 n = 32 n = 34
SVRR, n (%) 14 (34%) 16 (29%) 12 (33%) 12 (28%) 12 (38%) 12 (35%)
[95% CI] [20, 51] [17, 42] [19, 51] [15, 44] [21, 56] [20, 54]
JAK2 mutation status Mutant Wild-type Mutant Wild-type Mutant Wild-type
n = 61 n = 29 n = 48 n = 25 n = 41 n = 20
SVRR, n (%) 23 (38%) 5 (18%) 17 (35%) 5 (20%) 17 (42%) 5 (25%)
[95% CI] [26, 51] [6, 36] [22, 51] [7, 41] [26, 58] [9, 49]
Abbreviations: 95% CI, 95% confidence interval; EOC, end of cycle; ITT, intention-to-treat; JAK2, Janus kinase 2; SVRR, spleen volume response rate.
aPer enrolling investigator. One patient was classified as “Other: lack of efficacy.”
bRelapsed/refractory or intolerant per updated stringent criteria (see Table S1).
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Median spleen volume response duration was also NR (95%CI
7.2 months, NR) in both the Stringent Criteria Cohort (n = 41
responders) and the Sensitivity Analysis Cohort (n = 34
responders).
At EOC6, median percent change in spleen volume from baseline
was −38% (range –73% to +115%) in the ITT Population and –37%
(−73% to −6%) in both the Stringent Criteria and Sensitivity Analysis
cohorts. Among 51 patients in the ITT Population who had spleen
volume assessments at both baseline and at EOC6, all but one (98%)
achieved some degree of reduction in spleen volume with fedratinib,
and all patients in the Stringent Criteria Cohort with assessments at
both timepoints (by definition, the Sensitivity Analysis Cohort) had
spleen volume reductions (Figure 1A). Reductions of ≥50% in spleen
size by palpation at EOC6 occurred in 31% of patients (n = 30) in the
ITT Population, 30% (n = 24) in the Stringent Criteria Cohort, and 36%
(n = 24) in the Sensitivity Analysis Cohort.
F IGURE 1 Waterfall plot of individual changes from baseline in spleen volume, A and symptom score, B, in patients with assessments at
baseline and end of cycle 6 (EOC6)
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Proportions of patients with ≥35% reductions from baseline in
spleen volume at EOC3 in the ITT Population, Stringent Criteria
Cohort, and Sensitivity Analysis Cohort were 40% (95%CI 30, 51),
43% (32, 55), and 41% (29, 54), respectively.
3.2.2 | Symptom response
The symptom response rate in the MFSAF Analysis Population (n = 90)
was 27% (95%CI 18, 37). Among patients with evaluable TSS data at
baseline and EOC6, 82% reported some decrease in symptom severity
with fedratinib (Figure 1B). Clinically meaningful improvements in
symptom scores were observed across all individual symptoms
(Table S2). Symptom response rates in the Stringent Criteria Cohort
(n = 74) and in the Sensitivity Analysis Cohort (n = 62) supported results
for the ITT Population; at EOC6, symptom response rates were 27%
(95%CI 17, 39) and 32% (21, 45), respectively.
Baseline platelet count did not appear to influence symptom
score reductions with fedratinib: symptom response rate at EOC6
was 39% (95%CI 22%, 58%) in the subgroup of patients with baseline
platelet counts of 50 to <100 × 109/L, and 20% (11%, 33%) in
patients with platelet counts ≥100 × 109/L.
3.3 | Safety
All 97 patients experienced at least one TEAE. The most commonly
reported non-hematologic TEAEs (any grade) were diarrhea (62%),
nausea (56%), vomiting (41%), constipation (21%), pruritus (18%), and
fatigue (16%). The most common hematological TEAEs were anemia
(49%) and thrombocytopenia (27%) (Table 3). Grade 3 or grade
4 TEAEs were reported for 63% of patients; rates of grade 3-4 anemia
and thrombocytopenia were 38% and 22%, respectively. In laboratory
assessments, the most commonly reported abnormalities were anemia
(99%), creatinine increase (74%), and thrombocytopenia (70%)
(Table S3).
Serious TEAEs were reported for 33 patients (34%), the most
common being pneumonia (4%) and pleural effusion (3%). Eleven
patients experienced a serious event that was considered treatment-
related; pneumonia was the only treatment-related serious TEAE
reported for more than one patient (n = 2).
Seven patients (7%) experienced a TEAE that led to death during
the treatment period or the 30-day follow-up period. The cause of
death was determined to be disease progression in four cases, and the
other three cases were due to TEAEs (pneumonia, cardiorespiratory
arrest, and shock) that were not considered to be related to study
treatment.
Proportions of patients with treatment interruptions of ≥7 days
or any fedratinib dose-reduction were 26% and 39%, respectively.
The most common reasons for interruptions or dose-reductions were
nausea (8%), anemia (8%), diarrhea (7%), and thrombocytopenia (6%).
Nineteen patients (20%) permanently discontinued fedratinib due to a
TEAE (regardless of causality); diarrhea and thrombocytopenia (n = 2
each) were the only TEAEs leading to discontinuation in >1 patient.
Treatment-related TEAEs led to permanent treatment discontinuation
TABLE 3 Treatment-emergent adverse events (TEAEs) reported in >10% of patients in the ITT population
Preferred term
ITT population (N = 97) Stringent criteria cohort (n = 79) Sensitivity analysis cohort (n = 66)
Any Grade n (%) Grade 3–4 n (%) Any Grade n (%) Grade 3–4 n (%) Any Grade n (%) Grade 3–4 n (%)
Diarrhea 60 (62) 4 (4) 51 (65) 3 (4) 44 (67) 3 (5)
Nausea 54 (56) 0 42 (53) 0 35 (53) 0
Anemia 47 (49) 37 (38) 44 (56) 35 (44) 39 (59) 31 (47)
Thrombocytopenia 26 (27) 21 (22) 21 (27) 16 (20) 20 (30) 15 (23)
Vomiting 40 (41) 0 35 (44) 0 31 (47) 0
Constipation 20 (21) 1 (1) 17 (22) 0 15 (23) 0
Pruritus 17 (18) 0 14 (18) 0 12 (18) 0
Fatigue 15 (16) 2 (2) 11 (14) 1 (1) 10 (15) 1 (2)
Cough 13 (13) 0 12 (15) 0 9 (14) 0
Headache 13 (13) 1 (1) 10 (13) 1 (1) 9 (14) 1 (2)
Urinary tract infection 12 (12) 0 11 (14) 0 11 (17) 0
Abdominal pain 12 (12) 2 (2) 9 (11) 1 (1) 8 (12) 1 (2)
Dyspnea 12 (12) 1 (1) 9 (11) 1 (1) 8 (12) 1 (2)
Asthenia 11 (11) 1(1) 10 (13) 1 (1) 7 (11) 1 (2)
Dizziness 11 (11) 0 9 (11) 0 7 (11) 0
Pyrexia 11 (11) 1 (1) 7 (9) 0 7 (11) 0
Note: TEAEs were classified according to the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1, and graded according to National Cancer
Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03.
Abbreviations: NR, not reported; TEAE, treatment-emergent adverse event.
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for 10 patients (10%), eight of whom had a grade 3 or grade 4 treat-
ment-related event (Table S4). Only two patients discontinued
fedratinib due to treatment-related anemia or thrombocytopenia
(n = 1 each). No report of thrombocytopenia was associated with a
major bleeding event.
For patients with a baseline platelet count of 50 to <100 × 109/L
(n = 33), the median number of fedratinib treatment cycles received
was seven (range 1-20), and for patients with platelet counts
≥100 × 109/L (n = 64) was six (1-18). Approximately 91% of patients
with baseline platelet counts of 50 to <100 × 109/L and 97% of
patients with baseline platelet counts ≥100 × 109/L received ≥80% of
their intended fedratinib dose on-study. Safety events were generally
similar between the two baseline platelet count subgroups (Table S5),
with the exception of a higher frequency of expected grade 3-4 hema-
tologic events in patients with lower baseline platelet counts: 46%
and 49% of patients with platelet counts of 50 to <100 × 109/L
experienced grade 3-4 anemia and thrombocytopenia, respectively, vs
34% and 8% of patients with baseline platelet counts ≥100 × 109/L.
Patients aged ≤65 years (n = 41) received a median of seven
treatment cycles (range 1-20) and those aged >65 years (n = 56)
received a median of six cycles (1-18). Approximately 98% of patients
aged ≤65 years and 93% of patients aged >65 years received ≥80% of
their intended fedratinib dose. The incidences of TEAEs were gener-
ally similar between these age-based subgroups.
No case of WE occurred in this study. Grade 3 encephalopathy
was reported in one patient with underlying portal hypertension and
esophageal varices, who experienced slight forgetfulness and no other
neurological signs or symptoms. The investigator, external experts,
and the Data Safety Monitoring Board for the study reached a con-
sensus on a final diagnosis of hepatic encephalopathy and the patient
experienced a full recovery.
4 | DISCUSSION
In this population of heavily pretreated patients with poor prognostic
features at baseline, approximately one-third of all patients achieved
the primary endpoint of ≥35% spleen volume reduction from baseline
at EOC6, and most patients had reductions in spleen volume during
fedratinib treatment. Patients in this study had substantial MF disease
burden, as evidenced by large median spleen size and spleen volume
at baseline, and almost all patients reported MFSAF symptoms at
study entry. One-third of patients had platelet counts below
100 × 109/L and more than one-half had hemoglobin levels below
10 g/dL. Clinically meaningful reductions in splenomegaly and symp-
tom burden with fedratinib in the ITT Population are supported by
analyses in patients who met stringent criteria for ruxolitinib
relapsed/refractory or intolerant. Moreover, outcomes in the Sensitiv-
ity Analysis Cohort, in which patients were allowed sufficient expo-
sure to fedratinib to determine lack or loss of response or intolerance,
also strongly support findings in the ITT population.
Other JAK inhibitors tested in patients with MF previously
treated with ruxolitinib are in late-stage clinical development. In the
phase III PERSIST2 trial of pacritinib, a JAK2/FLT3 inhibitor, 6 of
62 patients (10%) who had received prior ruxolitinib therapy achieved
a ≥35% spleen volume reduction with pacritinib at 24 weeks.30 Simi-
larly, in the phase III SIMPLIFY-2 study of momelotinib, a JAK1/JAK2
inhibitor, 7 of 104 patients (7%) who had previously received
ruxolitinib achieved a spleen volume response with momelotinib.31
These low response rates emphasize the difficulty of attaining future
responses in patients with MF previously treated with ruxolitinib.
Acknowledging differences in study designs and the absence of head-
to-head comparisons, results of JAKARTA2 compare favorably with
those for other JAK inhibitors in similar patient populations.
In the current study, more than 90% of patients with baseline
platelet counts of 50 to <100 × 109/L received ≥80% of their
intended fedratinib dose; treatment was generally tolerable, and
spleen volume and symptom response rates were comparable to
rates for patients who entered the study with platelet counts
≥100 × 109/L. Similarly, baseline platelet count did not significantly
influence spleen response rates in the phase III JAKARTA trial of
fedratinib in JAK-inhibitor-naive patients with intermediate-2 or high-
risk MF.32 Even though ruxolitinib, the only other approved JAK inhib-
itor for MF, can be used at lower doses (5 or 10 mg twice-daily) in
patients with MF who have platelet counts of 50 to <100 × 109/L, it
may be at the expense of drug efficacy.9,33
Hematologic events are anticipated with JAK inhibitors based on
their mechanism of action.34 As expected, grade 3 or 4 cytopenias
were more commonly reported in patients who began the study with
platelet counts of 50 to <100 × 109/L. Importantly, cytopenias were
rarely cause for permanent fedratinib treatment discontinuation,
suggesting that these events could be managed effectively with dose
modifications, temporary treatment interruptions, and transfusions.
No report of thrombocytopenia was associated with a major bleeding
event.
The most frequent TEAEs in this study were low-grade gastroin-
testinal events. Clinical data suggest that taking fedratinib with a high-
fat meal improves gastrointestinal tolerability with minimal effect on
bioavailability.35 Strategies for prevention and management of gastro-
intestinal effects include prophylaxis for nausea or vomiting with anti-
emetics (eg, 5-HT3 receptor antagonists; dimenhydrinate and
anticholinergic and antimuscarinic agents can confound CNS symp-
toms and should be taken with caution), therapeutic use of antidiar-
rheals at onset of symptoms, and fedratinib dose modifications if
toxicity continues despite supportive treatment.
As mentioned, fedratinib clinical trials were placed on clinical hold
by the US FDA in November 2013 following reports of suspected
WE, a neurologic emergency resulting from thiamine (vitamin B1) defi-
ciency, and the clinical development program was subsequently termi-
nated by the sponsor. The clinical hold was lifted in August 2017 after
additional safety data were provided to the FDA. The fedratinib pre-
scribing information includes a Boxed Warning for encephalopathy,
including WE, based on eight reported cases observed in more than
600 patients treated with multiple doses of fedratinib in clinical tri-
als.21 Among the eight suspected WE cases; seven patients were tak-
ing fedratinib 500 mg/day at the time of symptom onset. The one
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case that occurred with fedratinib 400 mg/day was a patient in
JAKARTA2 who was determined in an independent review by exter-
nal experts to have hepatic encephalopathy, not WE. While most
events resolved (some involved persistent deficits, including memory
loss, cognitive impairment, and dizziness), one patient with head and
neck cancer metastatic to the brain and significant predisposing fac-
tors for WE, including difficulty eating and weight loss, had a fatal out-
come. Retrospective analysis of the potential events suggested that
all affected patients had considerable concomitant conditions known
to predispose to WE in any population (eg, underlying malnutrition,
nausea, vomiting, diarrhea).36,37 Importantly, preclinical data from ani-
mal models show that fedratinib, administered at clinically-relevant
doses, does not inhibit thiamine transport either from the GI to
plasma or from plasma to brain, nor does it lead to neurologic changes
associated with thiamine deficiency.38,39
Risk-mitigation strategies for WE and gastrointestinal TEAEs,
including routine monitoring of thiamine and thiamine supplementa-
tion as appropriate, and proactive treatment of gastrointestinal events
with the use of anti-emetics and antidiarrheals, are being evaluated in
the ongoing fedratinib phase III clinical program (FREEDOM
[ClinicalTrials.gov NCT03755518] and FREEDOM2 [NCT03952039])
assessing the efficacy and safety of fedratinib in patients with
intermediate-2 or high-risk MF previously treated with ruxolitinib.
Early study termination of JAKARTA2 may have led to underesti-
mation of fedratinib response. Spleen volume reductions of ≥35%
from baseline occurred in a higher proportion of patients who had the
opportunity to complete three cycles of fedratinib treatment than the
rate reported in the ITT analysis at EOC6; thus, patients who were
responding to fedratinib therapy may have been discontinued due to
the clinical hold before a cycle six measure was taken and would have
been considered nonresponders. Early termination also prevented
assessment of longer-term efficacy and safety of fedratinib treatment.
Currently, the longest exposure to fedratinib therapy occurred in the
extension portion of a phase I dose-finding and expansion study of
fedratinib in adult patients with MF (ClinicalTrials.gov NCT00631462,
NCT00724334).40,41 In an interim analysis from that study, 23 of
59 patients (39%) had received long-term fedratinib treatment for a
median 30 cycles (range 13-44) at a median current fedratinib dose of
440 mg.41 No unexpected safety signals emerged during long-term
fedratinib therapy.41 Long-term outcomes with fedratinib in patients
previously treated with ruxolitinib are currently under investigation in
the aforementioned FREEDOM and FREEDOM2 studies.
Eligibility criteria for the JAKARTA2 study required a relatively
limited degree of ruxolitinib exposure as sufficient to determine
ruxolitinib failure at enrollment. However, the median prior ruxolitinib
treatment duration in the ITT Population was 10.7 months, and out-
comes in the Stringent Criteria and Sensitivity Analysis cohorts, which
included patients with greater prior ruxolitinib exposure than initially
protocol-specified, were consistent with those of the ITT Population.
This rigorous updated analysis of JAKARTA2 data demonstrates
that patients with advanced MF who were substantially pretreated with
ruxolitinib could attain robust spleen responses and reduced symptom
burden with fedratinib. The efficacy of fedratinib was confirmed in the
subgroup of JAKARTA2 patients who met stringent criteria for
ruxolitinib relapsed, refractory, or intolerant, and in the sensitivity anal-
ysis comprising patients who were least affected by the fedratinib clini-
cal hold and early study termination. Fedratinib is an important new
treatment option for patients with MF, particularly those who have pre-
viously been treated with Ruxolitinib, as well as those patients with low
pretreatment platelet counts or hemoglobin levels.
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